Sanhaocao Biotechnology-B's mid-year report for 2024 shows that for the six months ended June 30, 2024, the company recorded a loss of 951 million yuan, a significant decrease from the profit of 650.6 million yuan in the same period last year. The revenue for the period was negative 101 million yuan, mainly due to the return of sales of the tetravalent influenza vaccine AdimFlu-S. Other income and gains decreased significantly to 671 million yuan, mainly because the funds received from CEPI were substantially recognized as other income in 2023. Research and development expenses decreased to 983 million yuan, as the related research and development activities for SCB-2019 (CpG 1018/aluminum adjuvant) have been completed. The total comprehensive loss for the period was 107.8 million yuan. As of June 30, 2024, the company's cash and cash equivalents amounted to 458.8 million yuan.

Sanhaocao Biotechnology-B's mid-year report for 2024 shows that for the six months ended June 30, 2024, the company recorded a loss of 951 million yuan, a significant decrease from the profit of 650.6 million yuan in the same period last year. The revenue for the period was negative 101 million yuan, mainly due to the return of sales of the tetravalent influenza vaccine AdimFlu-S. Other income and gains decreased significantly to 671 million yuan, mainly because the funds received from CEPI were substantially recognized as other income in 2023. Research and development expenses decreased to 983 million yuan, as the related research and development activities for SCB-2019 (CpG 1018/aluminum adjuvant) have been completed. The total comprehensive loss for the period was 107.8 million yuan. As of June 30, 2024, the company's cash and cash equivalents amounted to 458.8 million yuan.